Primary Boosters and Deterrents
Topical and oral retinoids, diclofenac gel, fluorouracil cream, imiquimod cream, vitamin D3, as well as surgical procedures including cryotherapy, excision and laser therapy are a few primary treatment options for porokeratosis. However, all these treatments take time to completely cure the condition.
Laser therapy has emerged as a highly sought-after treatment line for porokeratosis. The doctor uses a laser device to completely destroy the affected patch of ski, allowing new skin to grow. A recent study involved the use of carbon dioxide laser ablation to treat the skin condition. The 585 nm flashlamp-pumped pulsed dye laser helped the patient affected by linear porokeratosis, reducing the symptom significantly. Another study focuses on a 62 years old patient affected by disseminated superficial actinic porokeratosis, who was treated using a Q-switched ruby laser, which is extensively utilized for treating pigmented skin conditions. This laser therapy offered considerable improvement with no clinical recurrences. With the surge in research activities exploring the potential of laser therapy for treatment of porokeratosis, the global market is on its way to capture higher momentum in the following years.
Market Research Future (MRFR) expects the porokeratosis treatment market to clock in a growth rate of around 6.0% between 2020 and 2027 (analysis period).
The porokeratosis treatment industry can be considered for type of porokeratosis, diagnosis and treatment, and end-user.
Depending on the type of porokeratosis, the major segments can be linear porokeratosis, Disseminated Actinic Porokeratosis (DSAP), Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN), punctate porokeratosis and porokeratosis of Mantoux.
Diagnosis and treatment-based segments are diagnosis as well as treatment. Based on diagnosis, the market caters to differential diagnosis, biopsy, and more.
Top industry end-users listed in the market study are diagnostic centers, hospitals and clinics, research and academic institutes, drug stores, and others.
Geographically, the porokeratosis treatment industry has been divided into Europe, America, MEA or Middle East and Africa and Asia Pacific or APAC.
The American market for porokeratosis treatment is the clear winner, thanks to the mounting number of disseminated superficial actinic porokeratosis cases in the United States. The accelerated renal transplant cases also heighten the demand, with more than 10.67% of total renal transplant recipients affected by porokeratosis. Surging kidney transplant cases are also experiencing increase in patients dealing with porokeratosis. Studies also reveal that over 661,000 US citizens are suffering from kidney failure while over 467,000 of them are on dialysis, which fosters the porokeratosis cases since this disease is common in 11% of patients affected by kidney issues.
Europe is the second most lucrative market for porokeratosis treatment, benefitting mostly from the rising involvement of the leading marketers. Surging incidences of the disease and frequent technical innovations by manufacturers and researchers are responsible for the market expansion in the region. The popular trend of increased focus on personal care, especially among the youth, should also facilitate market growth for porokeratosis treatment, particularly in France and Germany.
The APAC market is scaling the growth trajectory at the fastest pace, in line with the rapidly soaring demand for porokeratosis treatment among the massive patient pool, along with the rising healthcare spending. The Mibelli type of porokeratosis is extremely common in the region. In 2013, the Mibelli type of porokeratosis affected 58% of total porokeratosis patients in Singapore, reports the Cases in Dermatology Journal. Apart from this, the expansive elderly population in Japan and its high susceptibility to the disease adds to the market value in the country.
The top firms in the market for porokeratosis treatment include Allergan (Republic of Ireland), Cutera (U.S.), Biolase Inc. (U.S.), Coherent, Inc. (U.S.), Alma Lasers (Israel), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Hologic Inc. (U.S.), IPG Photonics Corporation (U.S.), Angiodynamics, Inc. (U.S.), Lumenis (U.S.), L’Oreal (France), Pfizer (U.S.), Biogen (U.S.), Valeant Pharmaceuticals (Canada), PhotoMedex, Inc. (U.S.), IRIDEX Corp. (U.S.), Beiersdorf AG (Germany), Coty Inc. (U.S.), to mention a few.
Many of these companies are focused on spending significantly on the development and introduction of cost-effective and more advanced products that are useful in porokeratosis treatment. Besides, they also strive to achieve licensing agreements to bolster their worldwide reach.